Literature DB >> 8453625

Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.

E F McClay1, K D Albright, J A Jones, R D Christen, S B Howell.   

Abstract

Tamoxifen (TAM) markedly increases the response rate of malignant melanoma to treatment with cisplatin (DDP), carmustine, and dacarbazine, and we have previously reported that there is a highly synergistic interaction between TAM and DDP with respect to the cytotoxic effect against the human melanoma cell line T-289 (E. F. Mc Clay et al., Cancer Res., 52: 6790-6796, 1992). The mechanism underlying synergy was investigated by examining the effect of selection for either DDP or TAM resistance on the magnitude of the synergy quantitated by median effect analysis. The combination index at 50% cell kill was 0.26 +/- 0.02 (SD) for parental T-289 cells (indicating marked synergy), 0.54 +/- 0.14 for cells selected for low-level DDP resistance (indicating moderate synergy), and 1.39 +/- 0.20 for cells selected for low-level TAM resistance (indicating antagonism). Thus, factors that regulate DDP sensitivity have a moderate effect on reducing the DDP/TAM synergy, but determinants of TAM sensitivity have a major effect. The known biochemical effects of TAM include antagonism of estrogen at the estrogen receptor (ER) and inhibition of calmodulin and protein kinase C activity. T-289 cells contained undetectable amounts of ER by the dextran-coated charcoal assay and expressed only trace amounts of ER mRNA, and another more avid ER antagonist, droloxifene, failed to interact synergistically with DDP. N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), a potent calmodulin antagonist, failed to demonstrate synergy with DDP, and activation of protein kinase C, instead of interacting antagonistically with DDP, yielded synergy. TAM did not alter the cell cycle phase perturbation produced by exposure to DDP alone. We conclude that the synergy between TAM and DDP is not mediated by the effects of TAM on the ER, calmodulin, protein kinase C, or cell cycle regulation. However, the factors that determine cellular sensitivity to TAM also determine whether TAM interacts synergistically with DDP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453625

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Primary malignant melanoma of the esophagus: long-term survival following pre- and postoperative adjuvant hormone/chemotherapy.

Authors:  Hirokazu Uetsuka; Yoshio Naomoto; Toshiya Fujiwara; Yasuhiro Shirakawa; Hirofumi Noguchi; Tomoki Yamatsuji; Minoru Haisa; Junji Matsuoka; Mehmet Gunduz; Kaiyo Takubo; Noriaki Tanaka
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

2.  Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK.

Authors:  Nathan M Weir; Karuppaiyah Selvendiran; Vijay Kumar Kutala; Liyue Tong; Shilpa Vishwanath; Murugesan Rajaram; Susheela Tridandapani; Shrikant Anant; Periannan Kuppusamy
Journal:  Cancer Biol Ther       Date:  2007-02-05       Impact factor: 4.742

3.  Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients.

Authors:  L Mastronardi; F Puzzilli; W T Couldwell; J O Farah; P Lunardi
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

4.  Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study.

Authors:  M Napolitano; F Keime-Guibert; A Monjour; C Lafitte; A Ameri; P Cornu; P Broët; J Y Delattre
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

Authors:  P Tang; G Roldan; P M A Brasher; D Fulton; W Roa; A Murtha; J G Cairncross; P A Forsyth
Journal:  J Neurooncol       Date:  2006-05-19       Impact factor: 4.130

Review 6.  Systemic therapy of malignant melanoma.

Authors:  J Hansson
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.064

7.  Tamoxifen elicits rapid transmembrane lipid signal responses in human breast cancer cells.

Authors:  M C Cabot; Z C Zhang; A E Giuliano
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

8.  AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment.

Authors:  Natalie A Daurio; Stephen W Tuttle; Andrew J Worth; Ethan Y Song; Julianne M Davis; Nathaniel W Snyder; Ian A Blair; Constantinos Koumenis
Journal:  Cancer Res       Date:  2016-03-28       Impact factor: 12.701

9.  Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines.

Authors:  B Nakata; K D Albright; R M Barton; S B Howell; G Los
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  S Y Sharp; M G Rowlands; M Jarman; L R Kelland
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.